Euro Pratik Sales Ltd
EUROPRATIKEuro Pratik Sales Ltd is coiled. The quarters are improving, yet the P/E sits at the 2nd percentile of its own 1-year range — the business is moving before the market.
The sharpest disagreement: profits are rising, but only 39% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (12 weeks in) while the P/E sits at the 2nd percentile of its own 1-year range. Underneath, the last four quarters read improving — profit +122.2% year on year, and 39% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Euro Pratik Sales Ltd trades at ₹246, in a confirmed uptrend and 12 weeks into that stage. That is −9.8% against its own 200-day average. It sits at 22% of a 52-week range of ₹215 to ₹353. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (4 weeks and counting).
Today the stock is in a confirmed uptrend — week 12 of stage 2, confirmed. At ₹246 it trades −9.8% versus its 200-day average and sits at 22% of its 52-week range (₹215–₹353).
Against the market, two honest reads. Cumulative: over the last 1.0 years the stock moved +5% while the NIFTY 500 moved +0% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (4 weeks and counting; last ahead the week of 2026-08-14) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Euro Pratik Sales Ltd trades at 29.1× P/E, about the cheapest it has ever traded. Its long-run median P/E is 34.3×, measured across 1.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 29.1× is about the cheapest it has ever traded, against a long-run median of 34.3× measured over 1.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +0.4% against a +4.7% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, Euro Pratik Sales Ltd was paying for profit growth of about 19.3% a year. Profit itself has compounded 10.6% a year over the past 2 years. Today the market pays 29.1× P/E, the 2nd percentile of its own 1-year range.
What the two numbers say together. The multiple is low against its own past, and the growth the price is paying for is above what this company has actually delivered. A multiple that looks low because earnings fell is not the same thing as a low bar to clear.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Euro Pratik Sales Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 5 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +18.0% | — | — | — |
| Profit | +1.3% | — | — | — |
| EPS | +0.4% | — | — | — |
| Share price | +4.7% | — | — | — |
4-Factor Sector Score
59.9/100 — rank 9 of 52 in Trading · 73% evidence confidence
Euro Pratik Sales Ltd scores 59.9 out of 100 against the 52 companies it is compared with in Trading, ranking 9. Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
The four contributions add to the total exactly: 15.1 + 19.5 + 15.3 + 10 = 59.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Euro Pratik Sales Ltd reported ₹103 Cr of revenue in the Jun 26 quarter, +58.5% year on year. That is the 5th straight quarter of year-on-year growth. Over 2 years it has compounded at 23.1% a year. The last full year, FY26, came in at ₹335 Cr. The last four reported quarters add to ₹373 Cr.
FY26 revenue came in at ₹335 Cr (+18.0% on the year), capping 2 years at 23.1% compound. The latest quarter (Jun 26) printed ₹103 Cr, +58.5% year on year — the 5th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +25.7% growth against the decade's 23.1% — the current year is running faster than its own long-run rate.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Euro Pratik Sales Ltd's operating margin is 26.0% in the Jun 26 quarter, −8.0 percentage points against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 34.0% to 36.0%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 26.0%, −8.0 pp against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 34.0%–36.0%.
🚨 Why the margin moved: operating margin went −8.5 pp year on year while gross margin went −10.1 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Euro Pratik Sales Ltd earned ₹20.0 Cr of net profit in the Jun 26 quarter, +122.2% year on year. It is the 3rd consecutive quarter of growth. Full-year FY26 profit was ₹77.0 Cr. The 2-year compound rate is 10.6%. That is 19.4% of the quarter's revenue. The same quarter a year earlier earned ₹9.0 Cr.
Jun 26 profit was ₹20.0 Cr, +122.2% year on year — the 3rd consecutive quarter of growth. On the full year, FY26 printed ₹77.0 Cr (+1.3%), and the 2-year compound rate is 10.6%.
Why profit moved: revenue contributed +58.5% and the margin −8.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +47.0% vs revenue +25.7%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 39% of Euro Pratik Sales Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹41.0 Cr of operating cash against ₹77.0 Cr of profit. After ₹61.0 Cr of capital spending, ₹−20.0 Cr was left as free cash.
FY26: operating cash of ₹41.0 Cr against reported profit of ₹77.0 Cr, leaving free cash of ₹−20.0 Cr after ₹61.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 39% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 39%: the cash cycle stretched 145 days between FY24 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 145 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Euro Pratik Sales Ltd's cash conversion cycle runs 320 days in FY26, up from 175 days in FY24. Capital spending ran ₹71.0 Cr over the last 2 years. At FY26 sales of ₹335 Cr each day of that cycle holds about ₹0.9 Cr, so roughly ₹294 Cr sits inside the business at any moment.
FY26: debtors at 106 days, inventory at 255 days — roughly 8.4 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 320 days, looser than FY24's 175.
The full loop: cash goes out to suppliers and production on day 0; stock waits 255 days to sell; customers pay about 106 days after that; and suppliers themselves are paid at 41 days — netting out to the 320-day cycle.
In money terms: at FY26 sales of ₹335 Cr, each day of the cycle holds about ₹0.9 Cr — so the 320-day loop keeps roughly ₹294 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹71.0 Cr over the last 2 fiscal years against ₹11.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Euro Pratik Sales Ltd earns a ROCE of 38% in FY26. Return on invested capital clears the cost of that capital by +14.8 percentage points, so growth here adds value rather than only size. The wiring behind it is 23.0% net margin on 0.84× asset turns.
FY26 ROCE is 38%.
Why the return is what it is — the wiring (FY26): 23.0% net margin × 0.84× asset turns × 1.28× balance-sheet leverage ≈ 24.7% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 26.8% − 12.0% = a +14.8 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Euro Pratik Sales Ltd carries total debt of ₹24.0 Cr against shareholder equity of ₹321 Cr as of Mar 26, a debt-to-equity of 0.07 — effectively unlevered. On the annual view that ratio went from 0.08 in FY25 to 0.07 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹24.0 Cr against shareholder equity of ₹321 Cr — a debt-to-equity of 0.07. On the annual view, debt-to-equity went from 0.08 (FY25) to 0.07 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Euro Pratik Sales Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — .
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Euro Pratik Sales Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Onix Solar Energy LtdONIXSOLAR | 70.9/100Favorable setup69% evidence | 28.9/35 Revenue 26.2% · PAT 100% · OPM change 23 pp 95% evidence | 18.3/25 ROCE 32% · OPM 30% 76% evidence | 10.3/20 P/E 24.4× · PEG — 15% evidence | 13.4/20 RS sector 68.4% · RS bench -3.5% · 1Y 49.1%12 of 12 weeks ahead 70% evidence | |
| Exact sum: 28.9 + 18.3 + 10.3 + 13.4 = 70.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Rashi Peripherals LtdRPTECH | 69.0/100Favorable setup75% evidence | LEADER | 24.9/35 Revenue 40.4% · PAT 50.2% · OPM change -0.3 pp 95% evidence | 14.7/25 ROCE 17% · OPM 3% 76% evidence | 10.7/20 P/E 17.1× · PEG — 15% evidence | 18.7/20 RS sector 51.6% · RS bench 69.1% · 1Y 176.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 14.7 + 10.7 + 18.7 = 69 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Nupur Recyclers LtdNRL | 67.9/100Favorable setup87% evidence | LEADER | 22.5/35 Revenue 40.6% · PAT 29.8% · OPM change 3.6 pp 95% evidence | 16.5/25 ROCE 15.1% · OPM 11.6% 95% evidence | 9.2/20 P/E 53.6× · PEG — 50% evidence | 19.7/20 RS sector 66.4% · RS bench 88.4% · 1Y 89.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 16.5 + 9.2 + 19.7 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Magnus Steel & Infra Ltd517320 | 67.5/100Thin evidence · provisional56% evidence | 27.8/35 Revenue 100% · PAT 100% · OPM change 1.6 pp 83% evidence | 18.5/25 ROCE 171% · OPM 21.3% 76% evidence | 9.2/20 P/E 92.5× · PEG — 15% evidence | 12.0/20 RS sector — · RS bench 46.1% · 1Y 1449.6%0 of 1 week ahead to 2026-06-28 25% evidence | |
| Exact sum: 27.8 + 18.5 + 9.2 + 12 = 67.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Vision Infra Equipment Solutions LtdVIESL | 67.3/100Thin evidence · provisional56% evidence | TURNING | 19.0/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 19.8/25 ROCE 22.6% · OPM 26% 95% evidence | 10.9/20 P/E 14.9× · PEG — 15% evidence | 17.6/20 RS sector 26.9% · RS bench 44.5% · 1Y 122.8%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 19.8 + 10.9 + 17.6 = 67.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Shankara Buildpro LtdBUILDPRO | 63.3/100Mixed-positive evidence63% evidence | BREAKING OUT | 25.6/35 Revenue 26.3% · PAT 41.9% · OPM change -0.2 pp 100% evidence | 17.3/25 ROCE 39% · OPM 3.2% 100% evidence | 10.4/20 P/E 22.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 12 weeks ahead 0% evidence |
| Exact sum: 25.6 + 17.3 + 10.4 + 10 = 63.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Ivalue Infosolutions LtdIVALUE | 60.4/100Mixed-positive evidence60% evidence | ASLEEP | 20.6/35 Revenue 5.4% · PAT 22.1% · OPM change 5.6 pp 95% evidence | 18.6/25 ROCE 25.4% · OPM 10% 95% evidence | 11.2/20 P/E 11.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -19.4%6 of 10 weeks ahead 0% evidence |
| Exact sum: 20.6 + 18.6 + 11.2 + 10 = 60.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Sudarshan Pharma Industries Ltd543828 | 60.3/100Mixed-positive evidence82% evidence | LEADER | 20.9/35 Revenue 32.9% · PAT 24.3% · OPM change 1.5 pp 95% evidence | 13.6/25 ROCE 15.1% · OPM 9.1% 76% evidence | 8.9/20 P/E 39.2× · PEG — 50% evidence | 16.9/20 RS sector 17.5% · RS bench 33.4% · 1Y 25.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 13.6 + 8.9 + 16.9 = 60.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Euro Pratik Sales Ltdthis pageEUROPRATIK | 59.9/100Mixed-positive evidence73% evidence | ASLEEP | 15.1/35 Revenue 23.9% · PAT 29% · OPM change -8 pp 100% evidence | 19.5/25 ROCE 38.4% · OPM 26% 100% evidence | 15.3/20 P/E 29.1× · PEG 0.62 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y 4.7%6 of 10 weeks ahead 0% evidence |
| Exact sum: 15.1 + 19.5 + 15.3 + 10 = 59.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 10Tembo Global Industries LtdTEMBO | 59.0/100Mixed-positive evidence80% evidence | TURNING | 22.2/35 Revenue 34% · PAT 55.7% · OPM change 5 pp 95% evidence | 18.4/25 ROCE 22.8% · OPM 16% 95% evidence | 11.3/20 P/E 10.2× · PEG — 15% evidence | 7.1/20 RS sector -17.4% · RS bench -4.5% · 1Y -10.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 18.4 + 11.3 + 7.1 = 59 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Mangalam Global Enterprise LtdMGEL | 58.7/100Mixed-positive evidence80% evidence | 25.7/35 Revenue 41.4% · PAT 100% · OPM change 0.5 pp 95% evidence | 15.8/25 ROCE 17% · OPM 1.9% 95% evidence | 11.1/20 P/E 13× · PEG — 15% evidence | 6.1/20 RS sector -14.5% · RS bench -0.2% · 1Y -3.5%6 of 7 weeks ahead to 2026-08-09 100% evidence | |
| Exact sum: 25.7 + 15.8 + 11.1 + 6.1 = 58.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -14.5% and the one-year return is -3.5%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 12Arisinfra Solutions LtdARIS | 57.6/100Mixed-positive evidence65% evidence | TURNING | 22.0/35 Revenue 45.3% · PAT 100% · OPM change 2 pp 95% evidence | 15.1/25 ROCE 15.6% · OPM 11% 95% evidence | 10.8/20 P/E 15.5× · PEG — 15% evidence | 9.7/20 RS sector — · RS bench -1.2% · 1Y -12.3%4 of 10 weeks ahead 25% evidence |
| Exact sum: 22 + 15.1 + 10.8 + 9.7 = 57.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Aayush Art and Bullion Ltd540718 | 56.4/100Thin evidence · provisional54% evidence | BREAKING OUT | 21.2/35 Revenue 100% · PAT — · OPM change 1.6 pp 35% evidence | 13.2/25 ROCE 18.9% · OPM 6% 76% evidence | 8.9/20 P/E 245× · PEG — 15% evidence | 13.1/20 RS sector -1.1% · RS bench 13.5% · 1Y 29.2%3 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 13.2 + 8.9 + 13.1 = 56.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Patel Retail LtdPATELRMART | 53.8/100Mixed-positive evidence65% evidence | ASLEEP | 18.1/35 Revenue 42.3% · PAT 59.7% · OPM change -2.2 pp 95% evidence | 14.3/25 ROCE 15.3% · OPM 6.1% 95% evidence | 10.8/20 P/E 16.9× · PEG — 15% evidence | 10.6/20 RS sector — · RS bench 2.8% · 1Y -18.4%5 of 10 weeks ahead 25% evidence |
| Exact sum: 18.1 + 14.3 + 10.8 + 10.6 = 53.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Prostarm Info Systems LtdPROSTARM | 52.0/100Mixed-positive evidence65% evidence | BASING | 17.1/35 Revenue 30.5% · PAT 19.1% · OPM change 1.4 pp 95% evidence | 16.1/25 ROCE 18% · OPM 8.5% 95% evidence | 10.5/20 P/E 22× · PEG — 15% evidence | 8.3/20 RS sector — · RS bench -12.2% · 1Y -35.5%0 of 10 weeks ahead 25% evidence |
| Exact sum: 17.1 + 16.1 + 10.5 + 8.3 = 52 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Fabtech Technologies LtdFABTECH | 50.8/100Thin evidence · provisional52% evidence | TURNING | 17.5/35 Revenue 14.2% · PAT 41% · OPM change 14.8 pp 71% evidence | 12.3/25 ROCE 13.6% · OPM 5.7% 95% evidence | 11.0/20 P/E 13.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead 0% evidence |
| Exact sum: 17.5 + 12.3 + 11 + 10 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Lloyds Enterprises LtdLLOYDSENT | 50.3/100Mixed-positive evidence75% evidence | TURNING | 18.1/35 Revenue 33% · PAT -21.4% · OPM change 9 pp 95% evidence | 11.3/25 ROCE 3.7% · OPM 16% 76% evidence | 9.1/20 P/E 93.3× · PEG — 15% evidence | 11.8/20 RS sector -5% · RS bench 8.7% · 1Y -6%10 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 11.3 + 9.1 + 11.8 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18BMW Ventures LtdBMW | 50.0/100Thin evidence · provisional55% evidence | 16.9/35 Revenue 18.5% · PAT 24.2% · OPM change -0.6 pp 95% evidence | 11.9/25 ROCE 12% · OPM 3.4% 76% evidence | 11.2/20 P/E 12.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -18.7%0 of 10 weeks ahead 0% evidence | |
| Exact sum: 16.9 + 11.9 + 11.2 + 10 = 50 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19SG Mart LtdSGMART | 48.9/100Mixed-negative evidence93% evidence | LEADER | 13.9/35 Revenue 10.4% · PAT 14.7% · OPM change 1.4 pp 100% evidence | 8.6/25 ROCE 10.2% · OPM 4.5% 100% evidence | 8.2/20 P/E 76.1× · PEG 1.92 65% evidence | 18.2/20 RS sector 34.9% · RS bench 51.7% · 1Y 106.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 8.6 + 8.2 + 18.2 = 48.9 · Decision use: Price leads the evidence: RS versus the benchmark is 51.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20Bizotic Commercial Ltd543926 | 48.7/100Thin evidence · provisional58% evidence | BASING | 19.8/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 18.6/25 ROCE 26.8% · OPM 8% 76% evidence | 9.7/20 P/E 34.1× · PEG — 50% evidence | 0.6/20 RS sector -86.7% · RS bench -18.3% · 1Y -72.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 18.6 + 9.7 + 0.6 = 48.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Yogi LtdYOGI | 47.9/100Thin evidence · provisional58% evidence | 20.3/35 Revenue 97.5% · PAT 68.1% · OPM change -5.9 pp 62% evidence | 9.9/25 ROCE 12.8% · OPM 2.6% 76% evidence | 9.5/20 P/E 54.1× · PEG — 15% evidence | 8.2/20 RS sector -6.5% · RS bench -2.1% · 1Y -11.1%2 of 12 weeks ahead 70% evidence | |
| Exact sum: 20.3 + 9.9 + 9.5 + 8.2 = 47.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Shiv Aum Steels LtdSHIVAUM | 47.4/100Thin evidence · provisional55% evidence | BREAKING OUT | 16.9/35 Revenue — · PAT — · OPM change 1.3 pp 45% evidence | 11.4/25 ROCE 8% · OPM 4.7% 95% evidence | 7.2/20 P/E 66.8× · PEG — 50% evidence | 11.9/20 RS sector — · RS bench 38.3% · 1Y —6 of 6 weeks ahead 25% evidence |
| Exact sum: 16.9 + 11.4 + 7.2 + 11.9 = 47.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Dhunseri Ventures LtdDVL | 46.8/100Mixed-negative evidence87% evidence | BREAKING OUT | 12.6/35 Revenue -20% · PAT 31.7% · OPM change -12 pp 95% evidence | 9.7/25 ROCE 6.7% · OPM 39% 95% evidence | 11.9/20 P/E 5.3× · PEG — 50% evidence | 12.6/20 RS sector -7.1% · RS bench 8% · 1Y -14.9%7 of 12 weeks ahead 100% evidence |
| Exact sum: 12.6 + 9.7 + 11.9 + 12.6 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Adani Enterprises LtdADANIENT | 45.5/100Mixed-negative evidence93% evidence | TURNING | 14.3/35 Revenue 18.1% · PAT 4.2% · OPM change 0 pp 100% evidence | 8.5/25 ROCE 5.8% · OPM 15% 100% evidence | 7.7/20 P/E 174× · PEG 1.96 65% evidence | 15.0/20 RS sector 8.6% · RS bench 23.9% · 1Y 38.4%10 of 12 weeks ahead 100% evidence |
| Exact sum: 14.3 + 8.5 + 7.7 + 15 = 45.5 · Decision use: Price leads the evidence: RS versus the benchmark is 23.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 25MMTC LtdMMTC | 44.8/100Mixed-negative evidence96% evidence | ASLEEP | 15.1/35 Revenue 0% · PAT 100% · OPM change -1270 pp 100% evidence | 8.0/25 ROCE 8.7% · OPM — 84% evidence | 15.3/20 P/E 46.1× · PEG 0.92 100% evidence | 6.4/20 RS sector -14.9% · RS bench -1.9% · 1Y -4.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 8 + 15.3 + 6.4 = 44.8 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 26State Trading Corporation of India LtdSTCINDIA | 42.5/100Mixed-negative evidence67% evidence | ASLEEP | 19.6/35 Revenue — · PAT 100% · OPM change -14.6 pp 67% evidence | 5.6/25 ROCE -0.9% · OPM — 80% evidence | 11.9/20 P/E 14× · PEG — 50% evidence | 5.4/20 RS sector -28.7% · RS bench -5.6% · 1Y -5.6%2 of 11 weeks ahead 70% evidence |
| Exact sum: 19.6 + 5.6 + 11.9 + 5.4 = 42.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27RRP Semiconductor LtdRRP | 41.1/100Thin evidence · provisional54% evidence | 11.4/35 Revenue -80% · PAT -80% · OPM change 3.3 pp 71% evidence | 5.4/25 ROCE -32.7% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.3/20 RS sector 65.3% · RS bench 0.8% · 1Y 66.5%0 of 1 week ahead 70% evidence | |
| Exact sum: 11.4 + 5.4 + 10 + 14.3 = 41.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Cropster Agro Ltd523105 | 40.7/100Mixed-negative evidence65% evidence | 16.0/35 Revenue 28.4% · PAT 6.5% · OPM change 2.1 pp 83% evidence | 11.3/25 ROCE 12.4% · OPM 8.7% 76% evidence | 10.1/20 P/E 31× · PEG — 15% evidence | 3.3/20 RS sector -72.7% · RS bench -62.7% · 1Y -83.2%0 of 1 week ahead to 2026-08-09 70% evidence | |
| Exact sum: 16 + 11.3 + 10.1 + 3.3 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Hexa Tradex LtdHEXATRADEX | 40.3/100Mixed-negative evidence65% evidence | BASING | 17.2/35 Revenue 0.4% · PAT 70.3% · OPM change 13.6 pp 71% evidence | 6.1/25 ROCE -0.1% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 7.0/20 RS sector -16.8% · RS bench -3.7% · 1Y -12.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.2 + 6.1 + 10 + 7 = 40.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Hardwyn India LtdHARDWYN | 40.2/100Mixed-negative evidence87% evidence | ASLEEP | 13.8/35 Revenue 2.6% · PAT -8.5% · OPM change -0.2 pp 95% evidence | 12.5/25 ROCE 4.8% · OPM 13% 95% evidence | 12.1/20 P/E 50.6× · PEG — 50% evidence | 1.8/20 RS sector -38.3% · RS bench -29.5% · 1Y -3.4%3 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 12.5 + 12.1 + 1.8 = 40.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31Blue Pearl Agriventures LtdBPAGRI | 39.8/100Mixed-negative evidence69% evidence | 20.5/35 Revenue 19.3% · PAT 59.1% · OPM change 0.3 pp 95% evidence | 6.3/25 ROCE 2.2% · OPM 3.3% 76% evidence | 8.7/20 P/E 514× · PEG — 15% evidence | 4.3/20 RS sector -33.5% · RS bench -82.5% · 1Y -91.2%1 of 12 weeks ahead 70% evidence | |
| Exact sum: 20.5 + 6.3 + 8.7 + 4.3 = 39.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 32Pervasive Commodities Ltd517172 | 38.3/100Thin evidence · provisional52% evidence | 12.7/35 Revenue 25.6% · PAT -8.3% · OPM change -6.1 pp 95% evidence | 5.6/25 ROCE 0% · OPM -10.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 12.7 + 5.6 + 10 + 10 = 38.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Riddhi Siddhi Gluco Biols Ltd524480 | 38.0/100Mixed-negative evidence82% evidence | FADING | 12.4/35 Revenue -38% · PAT 38.4% · OPM change -2.8 pp 95% evidence | 6.6/25 ROCE 2.7% · OPM -3% 76% evidence | 6.5/20 P/E 37.3× · PEG — 50% evidence | 12.5/20 RS sector 10.5% · RS bench 25.4% · 1Y 33.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 12.4 + 6.6 + 6.5 + 12.5 = 38 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 34PTC India LtdPTC | 36.6/100Mixed-negative evidence82% evidence | BASING | 11.2/35 Revenue 13.3% · PAT -43.1% · OPM change -3.9 pp 95% evidence | 12.6/25 ROCE 13.4% · OPM 3.1% 76% evidence | 9.7/20 P/E 8.8× · PEG — 50% evidence | 3.1/20 RS sector -21.6% · RS bench -9.8% · 1Y -13%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.2 + 12.6 + 9.7 + 3.1 = 36.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Neueon Corporation LtdNEUEON | 35.6/100Thin evidence · provisional59% evidence | ASLEEP | 9.1/35 Revenue 17.8% · PAT -80% · OPM change -1039 pp 71% evidence | 3.7/25 ROCE -40.4% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.8/20 RS sector 12.7% · RS bench -1.5% · 1Y —1 of 12 weeks ahead 70% evidence |
| Exact sum: 9.1 + 3.7 + 10 + 12.8 = 35.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 36Kothari Industrial Corporation LtdKOTIC | 34.2/100Adverse evidence63% evidence | BASING | 18.8/35 Revenue 75.9% · PAT -80% · OPM change -41.8 pp 71% evidence | 1.6/25 ROCE -28.9% · OPM -43% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.8/20 RS sector -58.6% · RS bench -43.5% · 1Y -77.5%0 of 9 weeks ahead 70% evidence |
| Exact sum: 18.8 + 1.6 + 10 + 3.8 = 34.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Shanti Overseas (India) LtdSHANTI | 32.3/100Thin evidence · provisional56% evidence | 11.2/35 Revenue -63.4% · PAT 100% · OPM change -200.5 pp 40% evidence | 4.5/25 ROCE -25.2% · OPM -216.5% 71% evidence | 13.1/20 P/E 3× · PEG — 50% evidence | 3.5/20 RS sector -60.4% · RS bench -49.7% · 1Y -47.1%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 11.2 + 4.5 + 13.1 + 3.5 = 32.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 38BN Agrochem LtdBNAGROCHEM | 32.2/100Adverse evidence77% evidence | ASLEEP | 12.9/35 Revenue 84.5% · PAT -61% · OPM change -9.4 pp 100% evidence | 4.4/25 ROCE 4.4% · OPM 2.3% 100% evidence | 9.0/20 P/E 117× · PEG — 15% evidence | 5.9/20 RS sector -16.7% · RS bench -35.6% · 1Y -46.5%4 of 10 weeks ahead 70% evidence |
| Exact sum: 12.9 + 4.4 + 9 + 5.9 = 32.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 39Uniphos Enterprises LtdUNIENTER | 30.4/100Adverse evidence69% evidence | BASING | 12.6/35 Revenue -77.1% · PAT 100% · OPM change -0.9 pp 71% evidence | 4.6/25 ROCE 0.8% · OPM — 80% evidence | 8.8/20 P/E 31.4× · PEG — 50% evidence | 4.4/20 RS sector -43.6% · RS bench -22% · 1Y -41%1 of 10 weeks ahead 70% evidence |
| Exact sum: 12.6 + 4.6 + 8.8 + 4.4 = 30.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 40Oswal Agro Mills LtdOSWALAGRO | 24.7/100Adverse evidence67% evidence | 2.8/35 Revenue -80% · PAT -80% · OPM change -21782.3 pp 95% evidence | 7.8/25 ROCE 2% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.1/20 RS sector -50.3% · RS bench -32% · 1Y -49.6%0 of 6 weeks ahead to 2026-08-16 70% evidence | |
| Exact sum: 2.8 + 7.8 + 10 + 4.1 = 24.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 41Mardia Samyoung Capillary Tubes Company LtdMSCTC | 56.9/100Thin evidence · provisional32% evidence | 20.8/35 Revenue 100% · PAT 100% · OPM change — 29% evidence | 15.2/25 ROCE 22.6% · OPM 15.3% 57% evidence | 8.6/20 P/E 687× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 74.6% · 1Y 93.7%6 of 12 weeks ahead to 2026-03-08 25% evidence | |
| Exact sum: 20.8 + 15.2 + 8.6 + 12.3 = 56.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 42Proventus Agrocom LtdPROV | 56.7/100Thin evidence · provisional48% evidence | BREAKING OUT | 19.6/35 Revenue — · PAT — · OPM change 0.2 pp 26% evidence | 12.4/25 ROCE 11.5% · OPM 1.8% 95% evidence | 13.1/20 P/E 42.8× · PEG — 50% evidence | 11.6/20 RS sector — · RS bench 26.9% · 1Y —12 of 12 weeks ahead 25% evidence |
| Exact sum: 19.6 + 12.4 + 13.1 + 11.6 = 56.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 43DC Infotech & Communication LtdDCI | 56.3/100Thin evidence · provisional35% evidence | 18.6/35 Revenue — · PAT — · OPM change 0.3 pp 24% evidence | 17.6/25 ROCE 22.9% · OPM 4.7% 76% evidence | 10.6/20 P/E 20.4× · PEG — 15% evidence | 9.5/20 RS sector — · RS bench -1.6% · 1Y — 25% evidence | |
| Exact sum: 18.6 + 17.6 + 10.6 + 9.5 = 56.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 44SK Minerals & Additives Ltd544584 | 55.8/100Thin evidence · provisional36% evidence | TURNING | 16.6/35 Revenue — · PAT — · OPM change 1.3 pp 39% evidence | 19.0/25 ROCE 26.2% · OPM 10.7% 76% evidence | 10.2/20 P/E 29.5× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 4 weeks ahead 0% evidence |
| Exact sum: 16.6 + 19 + 10.2 + 10 = 55.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 45Monika Alcobev LtdMONIKA | 54.0/100Thin evidence · provisional22% evidence | 16.4/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 17.0/25 ROCE 21% · OPM 15% 57% evidence | 10.6/20 P/E 20.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -10.9%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 16.4 + 17 + 10.6 + 10 = 54 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 46Shah Foods Ltd519031 | 53.6/100Thin evidence · provisional18% evidence | TURNING | 17.1/35 Revenue — · PAT — · OPM change -10.7 pp 7% evidence | 15.3/25 ROCE — · OPM 18% 30% evidence | 8.8/20 P/E 276× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 103.9% · 1Y —4 of 4 weeks ahead 25% evidence |
| Exact sum: 17.1 + 15.3 + 8.8 + 12.4 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 47Pramara Promotions LtdPRAMARA | 51.7/100Thin evidence · provisional47% evidence | 16.6/35 Revenue — · PAT — · OPM change -1 pp 15% evidence | 13.9/25 ROCE 15.2% · OPM 15% 71% evidence | 6.9/20 P/E 51.3× · PEG — 50% evidence | 14.3/20 RS sector 7.9% · RS bench 29% · 1Y 34.5%10 of 12 weeks ahead to 2026-04-19 70% evidence | |
| Exact sum: 16.6 + 13.9 + 6.9 + 14.3 = 51.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 48Manbro Industries Ltd512595 | 50.9/100Thin evidence · provisional22% evidence | 18.3/35 Revenue — · PAT — · OPM change 32.8 pp 5% evidence | 13.1/25 ROCE — · OPM 6.6% 23% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.5/20 RS sector -17.3% · RS bench 37.2% · 1Y 62.6%12 of 12 weeks ahead to 2026-05-03 70% evidence | |
| Exact sum: 18.3 + 13.1 + 10 + 9.5 = 50.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 49Le Merite Exports LtdLEMERITE | 47.2/100Thin evidence · provisional40% evidence | 18.9/35 Revenue — · PAT — · OPM change 0.9 pp 15% evidence | 9.1/25 ROCE 8.6% · OPM 2.8% 71% evidence | 9.3/20 P/E 87× · PEG — 15% evidence | 9.9/20 RS sector -9% · RS bench 15% · 1Y 28.1%2 of 12 weeks ahead to 2026-05-17 70% evidence | |
| Exact sum: 18.9 + 9.1 + 9.3 + 9.9 = 47.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 50Satani Bearings Ltd505703 | 45.2/100Thin evidence · provisional38% evidence | TURNING | 20.5/35 Revenue — · PAT 100% · OPM change — 33% evidence | 4.7/25 ROCE 1% · OPM -3.7% 76% evidence | 8.6/20 P/E 5197× · PEG — 15% evidence | 11.4/20 RS sector — · RS bench 24.9% · 1Y 176.6%1 of 11 weeks ahead 25% evidence |
| Exact sum: 20.5 + 4.7 + 8.6 + 11.4 = 45.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 51Keto Motors Ltd537392 | 43.3/100Thin evidence · provisional38% evidence | TURNING | 16.3/35 Revenue — · PAT 100% · OPM change — 33% evidence | 6.0/25 ROCE -0.3% · OPM 10.7% 76% evidence | 8.5/20 P/E 7503× · PEG — 15% evidence | 12.5/20 RS sector — · RS bench 272.8% · 1Y —4 of 4 weeks ahead 25% evidence |
| Exact sum: 16.3 + 6 + 8.5 + 12.5 = 43.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 52A-1 LtdA1L | 41.0/100Thin evidence · provisional50% evidence | 16.2/35 Revenue 8.3% · PAT -30.6% · OPM change -0.9 pp 53% evidence | 10.7/25 ROCE 10.6% · OPM 2.9% 57% evidence | 8.8/20 P/E 383× · PEG — 15% evidence | 5.3/20 RS sector -24.5% · RS bench -16% · 1Y -8.6%6 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 16.2 + 10.7 + 8.8 + 5.3 = 41 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Euro Pratik Sales Ltd's share price today?
Euro Pratik Sales Ltd trades at ₹246, +4.7% over the past year. The company is valued at ₹2,511 Cr. The stock sits at 22% of its 52-week range of ₹215–₹353, −9.8% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 12 weeks in. — as of 11 September 2026.
What were Euro Pratik Sales Ltd's latest quarterly results?
Euro Pratik Sales Ltd reported revenue of ₹103 Cr and net profit of ₹20.0 Cr for the Jun 26 quarter. Revenue rose 58.5% and profit rose 122.2% year on year. Earnings per share were ₹1.84. The operating margin was 26.0%, 8.0 pp lower than a year earlier. — as of 11 September 2026.
What is Euro Pratik Sales Ltd's revenue?
Euro Pratik Sales Ltd reported revenue of ₹103 Cr in the Jun 26 quarter, +58.5% year on year. For the full FY26 fiscal year, revenue was ₹335 Cr (+18.0%). Over the last 2 years revenue compounded at 23.1% a year. — as of 11 September 2026.
What is Euro Pratik Sales Ltd's profit?
Euro Pratik Sales Ltd earned ₹20.0 Cr of net profit in the Jun 26 quarter, +122.2% year on year — the 3rd straight quarter of growth. Full-year FY26 profit was ₹77.0 Cr. The operating margin ran 26.0% in the latest quarter. — as of 11 September 2026.
What is Euro Pratik Sales Ltd's market cap?
Euro Pratik Sales Ltd's market capitalisation is ₹2,511 Cr at a share price of ₹246. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Euro Pratik Sales Ltd's P/E ratio?
Euro Pratik Sales Ltd trades at a P/E of 29.1×, at the 2nd percentile of its own 1-year range, against a long-run median of 34.3×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Euro Pratik Sales Ltd pay a dividend?
Yes — Euro Pratik Sales Ltd's dividend payout was 3% of profit in FY26, and it recorded a payout in 1 of its last 3 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Euro Pratik Sales Ltd overvalued?
On its own history, Euro Pratik Sales Ltd looks cheap: its P/E of 29.1× has been cheaper only 2% of the time in 1 years (long-run median 34.3×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Euro Pratik Sales Ltd growing?
Yes — Euro Pratik Sales Ltd is growing: latest-quarter revenue +58.5% year on year, profit +122.2%, and the margin −8.0 pp at 26.0%. The 2-year compound rates are 23.1% (revenue) and 10.6% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Euro Pratik Sales Ltd performing?
Euro Pratik Sales Ltd is in a confirmed uptrend, 12 weeks in. Its latest quarter's revenue rose 58.5% and profit rose 122.2% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
Is Euro Pratik Sales Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 12 of stage 2), trading −9.8% versus its 200-day average and at 22% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Euro Pratik Sales Ltd beating the market?
Not lately — on a trailing-13-week view Euro Pratik Sales Ltd is currently behind the NIFTY 500 (4 weeks and counting; last ahead the week of 2026-08-14), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.0 years the stock moved +5% against the NIFTY 500's +0% — ahead of the index over the full window. — as of 11 September 2026.
Will Euro Pratik Sales Ltd's share price go up?
This page publishes no price forecast for Euro Pratik Sales Ltd. What it measures instead: the share price is ₹246, the price is in a confirmed uptrend 12 weeks in. Its P/E of 29.1× sits at the 2nd percentile of its own 1-year range. — as of 11 September 2026.
Who owns Euro Pratik Sales Ltd?
Promoters hold 73.9% of Euro Pratik Sales Ltd, foreign institutions 0.6%, domestic institutions 4.5% and the public 21.1% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.
Does Euro Pratik Sales Ltd have too much debt?
No — Euro Pratik Sales Ltd's debt-to-equity is 0.08, and operating profit covers the interest bill 38×. FY26 borrowings were ₹24.0 Cr against equity of ₹310 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Euro Pratik Sales Ltd's capex?
Euro Pratik Sales Ltd spent ₹71.0 Cr on capital expenditure over the last 2 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹61.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Euro Pratik Sales Ltd's cash flow?
Euro Pratik Sales Ltd generated ₹41.0 Cr of operating cash flow in FY26 and ₹−20.0 Cr of free cash flow after ₹61.0 Cr of capital spending. Reported profit that year was ₹77.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Euro Pratik Sales Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 39% of Euro Pratik Sales Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹41.0 Cr against reported profit of ₹77.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 11 September 2026.
Where is Euro Pratik Sales Ltd in its business cycle?
Euro Pratik Sales Ltd's FY26 operating margin was 34.0%, against a 3-year band of 34.0%–36.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 26.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does Euro Pratik Sales Ltd's price assume?
At its price on 13 June 2026, Euro Pratik Sales Ltd was priced for profit growth of about 19.3% a year. Profit itself has compounded 10.6% a year over the past 2 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the Euro Pratik Sales Ltd story?
The sharpest disagreement: profits are rising, but only 39% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Euro Pratik Sales Ltd a stock worth studying right now?
This is not investment advice. The machine read: Euro Pratik Sales Ltd is coiled. The quarters are improving, yet the P/E sits at the 2nd percentile of its own 1-year range — the business is moving before the market. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!